CLINICAL TRIALS PROFILE FOR HISTAMINE POSITIVE
✉ Email this page to a colleague
All Clinical Trials for HISTAMINE POSITIVE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00206440 ↗ | Nexium Study To Suppress Nausea During Chemotherapy | Terminated | AstraZeneca | Phase 3 | 2005-08-01 | This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy. |
| NCT00206440 ↗ | Nexium Study To Suppress Nausea During Chemotherapy | Terminated | Baylor Breast Care Center | Phase 3 | 2005-08-01 | This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy. |
| NCT00311051 ↗ | Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite | Withdrawn | Research Center Borstel | Phase 2/Phase 3 | 2005-04-01 | The purpose of this study is to examine wether the combination of Ramatroban/Montelukast is as effective as Montelukast alone in patients with mild to moderate atopic asthma (GINA I and II) sensitive to house dust mite. The test is performed by a specific inhalative provocation. |
| NCT00359138 ↗ | The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2006-02-01 | This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single center study in subjects with positive histamine skin prick test and a positive RadioAllergoSorbent Test (RAST) (class > 2) to one of the tested standardized allergenic extracts: tree pollen, cat dander, house dust mite, or a mixture of five grass pollens. Subjects will be randomized to desloratadine 5 mg once daily, levocetirizine 5mg once daily, or placebo once daily for 8 days of treatment followed by 11 days of skin testing after discontinuation of the antihistamine treatment phase. The duration of the suppressive effects of desloratadine on cutaneous allergen-induced wheal and flare responses after discontinuation of a one-week treatment will be established. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HISTAMINE POSITIVE
Condition Name
Clinical Trial Locations for HISTAMINE POSITIVE
Trials by Country
Clinical Trial Progress for HISTAMINE POSITIVE
Clinical Trial Phase
Clinical Trial Sponsors for HISTAMINE POSITIVE
Sponsor Name
